NasdaqGS:BCRXBiotechs
BioCryst Pharmaceuticals (BCRX) Quarterly Loss Of US$721.8m Challenges Bullish Earnings Narratives
BioCryst Pharmaceuticals (BCRX) opened 2026 with Q1 revenue of US$156.4 million and a basic EPS loss of US$2.98, compared with Q1 2025 revenue of US$145.5 million and essentially breakeven EPS of US$0.00. Over the same period, trailing 12 month EPS shifted from a profit of US$1.26 to a loss of US$2.10. Over the past year, revenue on a trailing 12 month basis moved from US$503.5 million to US$885.7 million, while net income moved from a profit of US$263.9 million in 2025 Q4 to a loss of...